Clinical trials: Diabetes
Diabetes Mellitus, Type II
Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus
The purposes of this study are to: Evaluate the safety and tolerability of the study drug. Measure how much of the study drug (HM-002-1005) and its breakdown product get into the bloodstream, and how long it takes the body to get…
- Trial name
- NCT06498284
- Testing
- HM-002-1005
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Hua Medicine Limited
Diabetic Foot Ulcer
Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers
The purpose of the following prospective, randomized, controlled clinical trial is to compare synthetic hybrid-scale fiber matrix (Restrata®, Acera Surgical, Inc.) with standard of care in treating diabetic foot ulcers in human…
- Trial name
- NCT04918784
- Testing
- Restrata®, Wound Dressing
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Acera Surgical, Inc.
Diabetic Foot Ulcers
Postmarket Study to Evaluate Biovance® in Diabetic Foot Ulcers
The purpose of this study is to compare the wound closure outcomes of subjects receiving diabetic foot ulcer treatment with and without the use of Biovance®.
- Trial name
- NCT02506452
- Testing
- Biovance®, Standard of Care, Diabetic Foot Ulcers
- Where
- 10 sites in United States
- Volunteers
- 51 people
- Sponsor
- Alliqua BioMedical, Inc
Diabetes Mellitus, Type 2
A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
The study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and placebo (a dummy medicine). Researchers will test semaglutide to see how well it works compared to placebo.
- Trial name
- PIONEER 11 (NCT04109547)
- Testing
- Oral semaglutide
- Where
- 66 sites in Algeria, China and 4 more
- Volunteers
- 521 people
- Sponsor
- Novo Nordisk A/S
Diabetic Foot, Arterial Occlusive Disease
Urokinase Therapy in Patients With Diabetic Foot Syndrome
The purpose of this study is to determine whether the additional therapy with low dose urokinase is more effective than only a conventional standard therapy concerning ulcer-healing, rate of major amputation and survival.
- Conditions
- Diabetic Foot, Arterial Occlusive Disease, Ischemia
- Trial name
- NCT00823225
- Testing
- standard therapy, Urokinase
- Where
- 6 sites in Germany
- Volunteers
- 5 people
- Sponsor
- medac GmbH
Diabetic Neuropathy
Study of DA-9801 to Treat Diabetic Neuropathy
To evaluate the effectiveness of DA-9801 at 300mg, 600mg, 900mg and placebo, in reducing pain in subjects with diabetic neuropathic pain compared to their baseline values.
- Trial name
- NCT01822925
- Testing
- DA-9801 300mg, DA-9801 600mg, DA-9801 900mg
- Where
- 14 sites in United States
- Volunteers
- 128 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Type 2 Diabetes Mellitus
Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes
The purpose of this study is to obtain information on efficacy and safety of SHR3824 over 24 weeks and 52 weeks in Chinese patients with Type 2 Diabetes.
- Trial name
- NCT03159052
- Testing
- SHR3824
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Use Dapagliflozin 10 mg, Saxagliptin 5 mg, Metformin 500 mg treat type 2 diabetes patients with controlled cancers
- Trial name
- GD-T2D (NCT07033585)
- Testing
- Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Type 1 Diabetes Mellitus
A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus
This trial is a monocentric, randomised, double-blind, active comparator, controlled, 3-period cross-over trial.
- Trial name
- NCT03916640
- Testing
- ADO09 formulation, Symlin®, Humulin®
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Adocia
Diabetes Mellitus, Type 1
A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes
This study has two parts. Each participant will receive a daily injection of insulin peglispro during one treatment period and a daily injection of insulin glargine during the other treatment period.
- Trial name
- NCT01771250
- Testing
- Insulin Peglispro, Insulin Glargine
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
Empagliflozin and metformin hydrochloride are two separate drugs. The combination of these two drugs in one tablet are used for the treatment of type 2 diabetes, along with diet and exercise, and can be used with other drugs, if…
- Trial name
- NCT06792968
- Testing
- Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets, Synjardy 5 mg/1000 mg film-coated tablets
- Where
- Russia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Gedeon Richter Plc.
Type 2 Diabetes
A Study of HS-20094 in Patients With T2DM
This is a 32-week, phase 2, randomized study, HS-20094 and placebo were double-blind, dulaglutide was open-label. Adults with T2D inadequately controlled with diet and exercise alone or with stable metformin, an HbA1c (glycated…
- Trial name
- NCT06901648
- Testing
- HS-20094, Dulaglutide, Palcebo
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Type II Diabetes Mellitus
Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
Primary Objective: To evaluate the ability of lixisenatide to modulate postprandial hyperlipidemia in particular, the effects on plasma changes in triglycerides.
- Trial name
- NCT02274740
- Testing
- LIXISENATIDE AVE0010, metformin
- Volunteers
- 2 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus
Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus
- Trial name
- NCT02737891
- Testing
- Tesofensine/Metoprolol
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Saniona
Healthy Participants
A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants
This study will assess the effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the effect of Erythromycin on AZD5004 in healthy adult male and female participants.
- Trial name
- NCT06948747
- Testing
- AZD5004, Rosuvastatin, Erythromycin
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight and Obesity
Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus
The study is designed to evaluate the preliminary efficacy, safety, population PK profile, and immunogenicity of CPX101 in subjects with obesity or overweight with weight related comorbidities but without diabetes mellitus.
- Trial name
- NCT06532578
- Where
- Australia
- Volunteers
- 240 people
- Sponsor
- Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
Diabetes, Endocrine, Nutritional and Metabolic Diseases (E00-E89)
COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy
The purpose of this research study is to collect information about a new treatment for Type 2 Diabetes Mellitus (T2DM), using a medical device called the Metabolic Neuromodulation System which is intended to help regulate blood…
- Trial name
- NCT02278068
- Testing
- Metabolic Neuromodulation System (MNS)
- Where
- 6 sites in New Zealand
- Volunteers
- 46 people
- Sponsor
- Metavention
Type 1 Diabetes Mellitus
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
- Trial name
- NCT01498185
- Testing
- Dapagliflozin
- Where
- 12 sites in United States
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
Diabetic Macular Edema
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
The purpose of this study is to demonstrate that two investigational treatment regimens have the potential to result in a superior visual acuity improvement as compared to a ranibizumab pro re nata (PRN=as needed) treatment…
- Trial name
- RETAIN (NCT01171976)
- Testing
- Ranibizumab
- Where
- 68 sites in Belgium, Czechia and 11 more
- Volunteers
- 373 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Primary Objective: To demonstrate the superiority of Sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control with metformin.
- Trial name
- NCT02926950
- Testing
- Sotagliflozin (SAR439954), Metformin
- Where
- 93 sites in United States, Canada and 2 more
- Volunteers
- 518 people
- Sponsor
- Lexicon Pharmaceuticals